Effect of Nebivolol and Olmesartan on 24-Hour Brachial and Aortic Blood Pressure in the Acute Stage of Ischemic Stroke

Table 1

Baseline, demographic, clinical, and laboratory characteristics of study participants.

Parameter	Overall	Nebivolol (5 mg/day)	Olmesartan (20 mg/day)	No-treatment	value
Age (years)	79.3 ± 8.2	80.7 ± 7.3	79.5 ± 9.5	77.7 ± 7.8	0.51
Male gender (, %)	22 (36.7)	5 (25.0)	6 (30.0)	11 (55.0)	0.11
Body weight (kg)	73.3 ± 9.6	75.2 ± 11.3	70.5 ± 7.5	74.2 ± 9.7	0.27
Height (m)	1.66 ± 0.1	1.65 ± 0.1	1.66 ± 0.1	1.68 ± 0.1	0.46
BMI (kg/m^2)	26.5 ± 3.5	27.5 ± 3.8	25.5 ± 3.6	26.4 ± 3.1	0.21
History of DM (, %)	24 (40.0)	7 (35.0)	5 (25.0)	12 (60.0)	0.07
History of hypertension (, %)	44 (73.3)	13 (65.0)	16 (80.0)	15 (75.0)	0.55
History of CAD (, %)	11 (18.3)	5 (25.0)	3 (15.0)	3 (15.0)	0.36
History of previous stroke (, %)	14 (23.3)	6 (30.0)	2 (10.0)	6 (30.0)	0.19
24-h brachial SBP (mmHg)	153.1 ± 16.9	153.4 ± 19.1	151.7 ± 14.0	154.3 ± 18.2	0.89
24-h brachial DBP (mmHg)	84.4 ± 9.9	83.1 ± 9.2	84.7 ± 7.5	85.4 ± 12.8	0.76
Serum urea (mg/dl)	45.8 ± 15.8	46.3 ± 17.7	45.5 ± 13.3	45.6 ± 16.9	>0.90
Serum creatinine (mg/dl)	1.1 ± 0.2	1.1 ± 0.3	1.0 ± 0.2	1.1 ± 0.2	0.84
Uric acid (mg/dl)	4.9 ± 1.3	4.9 ± 1.1	5.0 ± 1.7	4.7 ± 1.3	0.72
Total cholesterol (mg/dl)	173.4 ± 44.5	160.8 ± 41.1	190.6 ± 39.3	168.9 ± 48.8	0.09
HDL cholesterol (mg/dl)	46.7 ± 11.8	44.4 ± 9.4	50.5 ± 13.5	45.4 ± 11.8	0.21
LDL cholesterol (mg/dl)	113.9 ± 39.3	104.5 ± 33.1	118.1 ± 35.2	119,1 ± 48.2	0.43
Triglycerides (mg/dl)	121.8 ± 44.0	112.2 ± 43.7	121.6 ± 46.3	131.6 ± 42.0	0.38

BMI = body mass index; CAD = coronary artery disease; DM = diabetes mellitus; DBP = diastolic blood pressure; HDL = high-density lipoprotein; LDL = low-density lipoprotein; SBP = systolic blood pressure; data are presented as mean ± SD or absolutes frequencies and percentages.